Cryoport, Inc. (NASDAQ:CYRX - Get Free Report) insider Edward J. Zecchini sold 51,500 shares of the stock in a transaction that occurred on Tuesday, June 10th. The stock was sold at an average price of $6.84, for a total value of $352,260.00. Following the sale, the insider now directly owns 90,411 shares of the company's stock, valued at approximately $618,411.24. The trade was a 36.29% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website.
Cryoport Stock Performance
Shares of NASDAQ CYRX traded up $0.13 during midday trading on Wednesday, hitting $6.91. The company's stock had a trading volume of 433,503 shares, compared to its average volume of 531,081. The firm has a market capitalization of $346.45 million, a price-to-earnings ratio of -2.04 and a beta of 1.85. The stock has a fifty day moving average price of $6.00 and a 200 day moving average price of $6.73. Cryoport, Inc. has a one year low of $4.58 and a one year high of $11.20. The company has a current ratio of 5.70, a quick ratio of 5.32 and a debt-to-equity ratio of 0.48.
Cryoport (NASDAQ:CYRX - Get Free Report) last announced its quarterly earnings data on Wednesday, May 7th. The company reported ($0.22) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.23) by $0.01. Cryoport had a negative net margin of 70.08% and a negative return on equity of 13.35%. The company had revenue of $41.04 million during the quarter, compared to analysts' expectations of $56.19 million. On average, research analysts forecast that Cryoport, Inc. will post -0.99 EPS for the current fiscal year.
Analysts Set New Price Targets
CYRX has been the topic of several research reports. UBS Group upped their price objective on shares of Cryoport from $10.00 to $11.00 and gave the company a "buy" rating in a report on Tuesday, April 1st. Needham & Company LLC reiterated a "buy" rating and issued a $11.00 price target on shares of Cryoport in a research note on Thursday, May 8th. Roth Mkm restated a "buy" rating and set a $15.00 price objective on shares of Cryoport in a research report on Tuesday, April 1st. Guggenheim reaffirmed a "buy" rating and issued a $10.00 target price on shares of Cryoport in a research report on Wednesday, April 16th. Finally, Morgan Stanley reduced their price target on Cryoport from $8.00 to $7.00 and set an "equal weight" rating for the company in a research note on Monday, May 5th. Two research analysts have rated the stock with a hold rating and five have given a buy rating to the stock. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average target price of $11.00.
Read Our Latest Research Report on CYRX
Institutional Inflows and Outflows
Several institutional investors have recently added to or reduced their stakes in the stock. Rhumbline Advisers increased its position in shares of Cryoport by 23.8% during the first quarter. Rhumbline Advisers now owns 78,320 shares of the company's stock valued at $476,000 after buying an additional 15,036 shares during the period. Acadian Asset Management LLC raised its position in shares of Cryoport by 106.4% in the 1st quarter. Acadian Asset Management LLC now owns 479,695 shares of the company's stock worth $2,911,000 after acquiring an additional 247,288 shares in the last quarter. Needham Investment Management LLC boosted its position in shares of Cryoport by 13.7% during the first quarter. Needham Investment Management LLC now owns 277,500 shares of the company's stock valued at $1,687,000 after purchasing an additional 33,500 shares in the last quarter. Jacobs Levy Equity Management Inc. grew its stake in Cryoport by 54.0% in the first quarter. Jacobs Levy Equity Management Inc. now owns 113,235 shares of the company's stock worth $688,000 after purchasing an additional 39,698 shares during the period. Finally, Banque Transatlantique SA bought a new position in Cryoport in the first quarter worth $369,000. 92.90% of the stock is currently owned by institutional investors.
About Cryoport
(
Get Free Report)
Cryoport, Inc provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services.
See Also
Before you consider Cryoport, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cryoport wasn't on the list.
While Cryoport currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
